Hepatitis C Drugs Market Technology Trends, Growth Analysis, New Strategies And Solution, Key Companies, Service, Component, Application and End User to Forecast By 2027
Hepatitis C virus is a blood-borne virus that is transmitted through needlestick injuries, organ transplant from a carrier, sexually or from infected mother to fetus. The virus infects liver cells and can lead to mild and transient effects such as easy bleeding, fatigue, yellow discoloration of skin and eyes. The virus can also lead to chronic and serious life-threatening conditions such as liver cirrhosis, liver cancer or liver failure. There are six distinct forms of hepatitis C virus based on its genotypes.
To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/1489
The Type 1 virus leads to around 60 -70% of global infections. Some of the methods used to diagnose hepatitis C include, blood tests for estimating viral load and genotyping and liver damage tests such as magnetic resonance elastography (MRE), transient elastography, and liver biopsy. Antiviral drugs are used for the treatment of infection caused due to hepatitis C. These drugs inhibit the growth of protease or polymerase enzyme of the virus. However, there is no vaccine for the prevention infections caused due to hepatitis C virus, which offers lucrative growth opportunities for market players.
Hepatitis C Drug Market Taxonomy
By Drug Class
- Hepatitis C Virus Protease Inhibitor
- Nucleoside/tide Polymerase Inhibitors
- NS5A Inhibitors
- Non-Nucleoside Polymerase Inhibitors
- Combinational drug
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Exclusive offer!!! Purchase the report at a discounted rate!!!
Apply Promo Code “CMIFIRST1000” and Get Up to 30% Discount
Quick Buy – Hepatitis C Drugs Market Research Report: https://bit.ly/3tQGEzO
Increasing prevalence of chronic hepatitis C to augment the market growth
Increasing number of people suffering from chronic hepatitis C is expected to boost growth of the global hepatitis C drug market. For instance, according to the World Health Organization (WHO), in 2017, around 71 million people were infected by chronic hepatitis C worldwide. Furthermore, WHO considers Eastern Mediterranean and European regions to be the most affected regions with the prevalence rate of 2.3% and 1.5%, respectively. According to the Centers for Disease Control and Prevention, around 2.7 million to 3.9 million people in the U.S. suffer from hepatitis C. Sharing of injection equipment, transfusion of infectious blood, sexually or from infected mother to infant can lead to easy transmission of the hepatitis C virus, which is further expected to contribute to growth of the global hepatitis C drug market.
Increasing focus of various governments to expand drug coverage is expected to boost growth of the global hepatitis C drug market. For instance, in 2018, the Ministry of Health and Long-Term Care of Ontario announced that all patients are eligible for Ontario Drug Benefit (ODP) irrespective of severity of their disease. In the same year, Thunder Bay group, HIV / AIDS / hepatitis C education and support services provider, expanded its access to medicines, as a result of successful negotiations between the provinces and drug manufacturers.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/market-insight/hepatitis-c-drugs-market-1489
Increasing number of drugs available for the tenement of hepatitis C is also expected to boost growth of the market over the forecast period. Moreover, direct acting antivirals (DAAs) help in the development of highly effective, INF-free hepatitis C drug regimen in contrast to standard treatment. The pipeline contains dual and triple DDA combinational therapy against hepatitis C virus. The effect of a combination drug is more significant compared to single regimen in the treatment of hepatitis C. Key players in the market are focused on approval and launch of new therapies. For instance, in 2016, Gilead submitted a new drug application to the U.S. FDA for the fixed-dose combination SOF/VEL/voxilaprevir for the treatment of HCV genotypes 1–6. Moreover, in January 2017, EMA granted assessment of SOF/VEL/voxilaprevir combination. Furthermore, in 2017, the U.S. FDA approved AbbVie’s Mavyret, a combination of glecaprevir and pibrentasvir for the treatment of hepatitis C.
However, high cost of therapies and denial for Medicaid patients is expected to hamper growth of the global hepatitis C drug market.
Major players operating in the global hepatitis C drug market include, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson, Bristol-Myers Squibb, Merck & Co. Inc., and Vertex Pharmaceuticals.
View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/hepatitis-c-drugs-market-2684
Table of Content
Global Hepatitis C Drugs Market Research Report
Section 1: Global Hepatitis C Drugs Industry Overview
Section 2: Global Economic Impact on Hepatitis C Drugs Industry
Section 3: Global Market Competition by Industry Producers
Section 4: Global Productions, Revenue (Value), according to Regions
Section 5: Global Supplies (Production), Consumption, Export, Import, geographically
Section 6: Global Productions, Revenue (Value), Price Trend, Product Type
Section 7: Global Market Analysis, on the basis of Application
Section 8: Hepatitis C Drugs Market Pricing Analysis
Section 9: Market Chain, Sourcing Strategy and Downstream Buyers
Section 10: Strategies and key policies by Distributors/Suppliers/Traders
Section 11: Key Marketing Strategy Analysis, by Market Vendors
Section 12: Market Effect Factors Analysis
Section 13: Global Hepatitis C Drugs Market Forecast
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
- CDN Newswire